Aspire Biopharma Holdings Inc. (NASDAQ: ASBP) has announced upcoming milestones for its pipeline of sublingual drug delivery products. The company plans to submit a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its high-dose sublingual aspirin in the second half of 2025, following a review of clinical trial results with the agency. Additionally, Aspire intends to finalize the formulation and manufacture of a sublingual semaglutide product and conduct an initial Phase 1 pharmacokinetic clinical cross-over study in the first half of 2026. For its needle-free, rapid-acting erectile dysfunction medication, Aspire plans to develop and validate the manufacturing process and produce a cGMP batch in early 2026, with a Phase 1 clinical test scheduled for the second or third quarter of 2026. Results of these clinical studies have not yet been presented and are expected in the future as the company advances its development programs.